Casi ningún lugar del mundo está libre de contaminación atmosférica
MARTES, 7 de marzo de 2023 (HealthDay News) — Un nuevo estudio es suficiente para quitarle el aliento: encontró que casi ningún lugar de la Tierra está libre de aire contaminado.El estudio “provee una profunda comprensión sobre el estado actual de la…
Learn MoreMotavizumab, Nirsevimab, Palivizumab Beneficial for RSV Prevention
TUESDAY, March 7, 2023 (HealthDay News) — Significant benefits are seen with motavizumab, nirsevimab, and palivizumab for prevention of respiratory syncytial virus (RSV) in infants and children, according to a review published online Feb. 17 in JAMA …
Learn MoreThere’s Almost Nowhere in the World Free of Air Pollution
TUESDAY, March 7, 2023 (HealthDay News) — A new study is enough to take your breath way: Nearly no place on Earth is free of air pollution, it found.The study “provides a deep understanding of the current state of outdoor air pollution and its impact…
Learn MoreUn panel de la FDA respalda una segunda vacuna contra el VSR para los estadounidenses mayores
JUEVES, 2 de marzo de 2023 (HealthDay News) — Tras horas de debate sobre preocupaciones por la seguridad, el miércoles un panel asesor de la Administración de Alimentos y Medicamentos (FDA) de EE. UU. recomendó la aprobación de una segunda vacuna con…
Learn MoreFDA Panel Backs Second RSV Vaccine for Older Americans
THURSDAY, March 2, 2023 (HealthDay News) — Following hours of discussion over safety concerns, a U.S. Food and Drug Administration advisory panel on Wednesday recommended approval of a second respiratory syncytial virus (RSV) vaccine, this one made b…
Learn MoreUn panel de la FDA respalda a la vacuna contra el VSR de Pfizer para los estadounidenses mayores
MIÉRCOLES, 1 de marzo de 2023 (HealthDay News) — En un apretado voto, los asesores de la Administración de Alimentos y Medicamentos (FDA) de EE. UU. recomendaron el martes la aprobación de una vacuna contra el virus sincitial respiratorio (VSR) que s…
Learn MoreFDA Panel Backs Second RSV Vaccine for Older Americans
THURSDAY, March 2, 2023 (HealthDay News) — Following hours of discussion over safety concerns, a U.S. Food and Drug Administration advisory panel on Wednesday recommended approval of a second RSV vaccine, this one made by GlaxoSmithKline, for use in …
Learn MoreFDA Panel Backs Pfizer RSV Vaccine for Older Americans
WEDNESDAY, March 1, 2023 (HealthDay News) — In a tight vote, U.S. Food and Drug Administration advisers on Tuesday recommended the approval of a respiratory syncytial virus (RSV) vaccine that could be used in Americans ages 60 years and older.The vac…
Learn MoreFDA Panel Backs Pfizer’s RSV Vaccine for Older Americans
WEDNESDAY, March 1, 2023 (HealthDay News) — In a tight vote, U.S. Food and Drug Administration advisors on Tuesday recommended the approval of an RSV vaccine that could be used in Americans ages 60 and up. The vaccine, known as RENOIR, was developed …
Learn MorePersistent Organ Damage Common One Year After COVID-19
TUESDAY, Feb. 28, 2023 (HealthDay News) — Organ impairment persists in 59 percent of individuals one year after COVID-19, according to a study published online Feb. 14 in Journal of the Royal Society of Medicine.Andrea Dennis, Ph.D., from Perspectum …
Learn More